Compare IART & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | ANAB |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2017 |
| Metric | IART | ANAB |
|---|---|---|
| Price | $13.23 | $44.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $15.00 | ★ $63.80 |
| AVG Volume (30 Days) | ★ 874.9K | 751.8K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,642,966,000.00 | $169,467,000.00 |
| Revenue This Year | $3.26 | $135.45 |
| Revenue Next Year | $2.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.99 | ★ 196.42 |
| 52 Week Low | $10.87 | $12.21 |
| 52 Week High | $27.13 | $45.32 |
| Indicator | IART | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 71.68 |
| Support Level | $12.81 | $40.52 |
| Resistance Level | $13.43 | $45.32 |
| Average True Range (ATR) | 0.57 | 2.66 |
| MACD | 0.24 | 0.36 |
| Stochastic Oscillator | 78.69 | 92.89 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).